Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €97.96 EUR
Change Today +2.69 / 2.83%
Volume 13.3K
As of 3:35 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

biotest ag (BIO) Snapshot

Open
€95.99
Previous Close
€95.27
Day High
€99.33
Day Low
€95.20
52 Week High
03/6/15 - €99.33
52 Week Low
08/12/14 - €68.50
Market Cap
1.3B
Average Volume 10 Days
4.1K
EPS TTM
€2.10
Shares Outstanding
6.6M
EX-Date
05/8/14
P/E TM
46.6x
Dividend
€0.57
Dividend Yield
0.58%
Current Stock Chart for BIOTEST AG (BIO)

Related News

No related news articles were found.

biotest ag (BIO) Related Businessweek News

No Related Businessweek News Found

biotest ag (BIO) Details

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.

2,137 Employees
Last Reported Date: 11/12/14
Founded in 1946

biotest ag (BIO) Top Compensated Officers

Chief Financial Officer, Head of Finances & C...
Total Annual Compensation: €459.0K
Chief Operating Officer and Member of Executi...
Total Annual Compensation: €353.0K
Compensation as of Fiscal Year 2013.

biotest ag (BIO) Key Developments

Biotest AG Reports Preliminary and Unaudited Operating Results for the Year 2014

Biotest AG reported preliminary and unaudited operating results for the year 2014. For the year, the company reported revenues increased to EUR 582.0 million. This represents an increase of 16.2% compared to the previous year EUR 500.8 million. On account of advanced research and development cost, additional expenses relating to the planed production capacity expansion at the headquarters in Dreieich, Germany, as well as overall lower margin business, especially in crisis regions, Group's earnings before interest and tax (EBIT) came in at EUR 53.4 million at the previous year EBIT level of EUR 53.8 million.

Biotest AG Presents at UniCredit und Kepler Cheuvreux 14th German Corporate Conference, Jan-21-2015 02:45 PM

Biotest AG Presents at UniCredit und Kepler Cheuvreux 14th German Corporate Conference, Jan-21-2015 02:45 PM. Venue: Villa Kennedy, Kennedyallee 70, D-60596 Frankfurt, Germany. Speakers: Bernhard R. M. Ehmer, Member of the Executive Board.

Biotest Encourages Efficacy of Indatuximab Ravtansine (BT-062) in Multiple Myeloma in Combination with Lenalidomide and Dexamethasone

Biotest presented new clinical data derived from an ongoing combination study with BT-062 at the 56th annual meeting of the American Society of Hematology (ASH) in San Francisco. The Phase I/IIa study (Study 983) in multiple myeloma is investigating the safety and efficacy of BT-062 in combination with lenalidomide and dexamethasone in patients who have not been responding (any more) to previous treatments. In the study, a total of 47 patients were treated with three different dosages up to maximum of 120 mg/m- BT-062, used in combination with lenalidomide and dexamethasone. Patients were treated until progression of the underlying disease or occurrence of unacceptable toxicities. 25 of the 47 patients enrolled are currently still on treatment, partly for up to 23 months. Currently available efficacy data were evaluated from those 41 patients who had at least two efficacy assessments since the start of the treatment. All of these heavily pretreated patients showed clinical benefit from the therapy, achieving a stable disease or better. 78% of these patients had an objective response which ranges from a partial response to stringent complete response. Up to now 10% of the patients had a complete remission. Even in patients previously treated with both lenalidomide and bortezomib, an objective response rate of 68% was obtained. The available data indicate that BT-062 is well tolerated in this combination regimen up to doses of 100 mg/m-. Among the patients treated with the maximal tolerated dose (100 mg/m-), even 83% had an objective response. Based on these encouraging data, it is planned to also evaluate safety and efficacy of BT-062 in combination with pomalidomide and dexamethasone in patients already exposed to lenalidomide and bortezomib. Besides the multiple myeloma cells also many solid tumors express high levels of the CD 138 receptor. Biotest is conducting a monotherapy phase I/IIa study (Study 989) in triple negative metastatic breast cancer and metastatic urinary bladder cancer in Belgium and Germany.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIO:GR €97.96 EUR +2.69

BIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIO.
View Industry Companies
 

Industry Analysis

BIO

Industry Average

Valuation BIO Industry Range
Price/Earnings 40.5x
Price/Sales 2.1x
Price/Book 2.3x
Price/Cash Flow 20.2x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTEST AG, please visit www.biotest.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.